×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KALV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/2
04:01 pm
kalv
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/31
09:27 pm
kalv
KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial [Yahoo! Finance]
Low
Report
KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial [Yahoo! Finance]
3/30
07:00 am
kalv
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
Medium
Report
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
3/26
10:49 am
kalv
KalVista Pharmaceuticals (KALV) had its price target raised by Stifel Nicolaus from $39.00 to $42.00. They now have a "buy" rating on the stock.
Medium
Report
KalVista Pharmaceuticals (KALV) had its price target raised by Stifel Nicolaus from $39.00 to $42.00. They now have a "buy" rating on the stock.
3/26
09:43 am
kalv
KalVista Pharmaceuticals (KALV) had its price target lowered by Citizens Jmp from $29.00 to $28.00. They now have a "market outperform" rating on the stock.
High
Report
KalVista Pharmaceuticals (KALV) had its price target lowered by Citizens Jmp from $29.00 to $28.00. They now have a "market outperform" rating on the stock.
3/26
08:02 am
kalv
KalVista Pharmaceuticals (KALV) had its price target raised by Needham & Company LLC from $35.00 to $36.00. They now have a "buy" rating on the stock.
High
Report
KalVista Pharmaceuticals (KALV) had its price target raised by Needham & Company LLC from $35.00 to $36.00. They now have a "buy" rating on the stock.
3/25
07:00 am
kalv
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
Low
Report
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
3/18
07:00 am
kalv
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
Medium
Report
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
Date
Time
Symbol
Company Name
Action
%Chg
3/25/2026
07:00 am
kalv
kalvista pharmaceuticals, inc.
MISS
Report
1.4%
kalvista pharmaceuticals, inc.
11/10/2025
04:30 pm
kalv
kalvista pharmaceuticals, inc.
BEAT
Report
5.3%
kalvista pharmaceuticals, inc.
9/11/2025
07:00 am
kalv
kalvista pharmaceuticals, inc.
MISS
Report
-9.4%
kalvista pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/27
05:50 pm
kalv
Form 4 KalVista Pharmaceuticals For: Mar 25 Filed by: VHCP Co-Investment Holdings III, LLC
Medium
Report
Form 4 KalVista Pharmaceuticals For: Mar 25 Filed by: VHCP Co-Investment Holdings III, LLC
3/25
04:36 pm
kalv
Form 10-KT KalVista Pharmaceuticals For: Dec 31
High
Report
Form 10-KT KalVista Pharmaceuticals For: Dec 31
3/25
07:17 am
kalv
Form 8-K KalVista Pharmaceuticals For: Mar 25
Low
Report
Form 8-K KalVista Pharmaceuticals For: Mar 25
3/10
06:47 pm
kalv
Form 4 KalVista Pharmaceuticals For: Mar 06 Filed by: Palleiko Benjamin L
Medium
Report
Form 4 KalVista Pharmaceuticals For: Mar 06 Filed by: Palleiko Benjamin L
2/24
07:45 pm
kalv
Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Audhya Paul K.
Low
Report
Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Audhya Paul K.
2/24
07:44 pm
kalv
Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Palleiko Benjamin L
Low
Report
Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Palleiko Benjamin L
2/24
07:43 pm
kalv
Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Yea Christopher
Low
Report
Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Yea Christopher
2/24
07:43 pm
kalv
Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Sweeny Nicole
Low
Report
Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Sweeny Nicole
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/9
Q1/2019 7/31/2019 EPS -0.420 ZacksConsensus -0.610 ActVsEst 0.190 - Beat
9.9%
3/23 Form SC 13G KalVista Pharmaceuticals Filed by: Ikarian Capital, LLC 8.8%
4/9 KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference 8.4%
12/7 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%
11/29 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.0%
7/19 Form 4 KalVista Pharmaceuticals For: Jul 17 Filed by: Cha Albert 4.4%
9/30 Form 4 KalVista Pharmaceuticals For: Sep 26 Filed by: SOLAND DANIEL B 4.3%
6/16 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
5/14 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
10/25 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. 3.2%
3/23 Form SC 13G KalVista Pharmaceuticals Filed by: Ikarian Capital, LLC 8.8%
4/9 KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference 8.4%
12/7 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%
11/29 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.0%
7/19 Form 4 KalVista Pharmaceuticals For: Jul 17 Filed by: Cha Albert 4.4%
9/30 Form 4 KalVista Pharmaceuticals For: Sep 26 Filed by: SOLAND DANIEL B 4.3%
6/16 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%
5/14 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
10/25 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. 3.2%
TOP News Decliners
3/10
Form 10-Q KalVista Pharmaceuticals For: Jan 31
-14.8%
3/10 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results -13.7%
4/30 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.7%
5/31 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.7%
12/26 Form 4 KalVista Pharmaceuticals For: Dec 20 Filed by: Crockett Thomas Andrew -6.8%
12/3 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. -6.8%
2/22 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.8%
7/1 Form 8-K KalVista Pharmaceuticals For: Jun 26 -4.5%
9/4 KalVista Pharmaceuticals: Our Verdict [Seeking Alpha] -4.3%
5/15 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its price target raised by analysts at Roth Capital from $25.00 to $30.00. They now have a "buy" rating on the stock. -4.2%
3/10 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results -13.7%
4/30 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.7%
5/31 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.7%
12/26 Form 4 KalVista Pharmaceuticals For: Dec 20 Filed by: Crockett Thomas Andrew -6.8%
12/3 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. -6.8%
2/22 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.8%
7/1 Form 8-K KalVista Pharmaceuticals For: Jun 26 -4.5%
9/4 KalVista Pharmaceuticals: Our Verdict [Seeking Alpha] -4.3%
5/15 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its price target raised by analysts at Roth Capital from $25.00 to $30.00. They now have a "buy" rating on the stock. -4.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: